Yuji Kasukawa
Loma Linda University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yuji Kasukawa.
Bone | 2003
Charles H. Rundle; Naohisa Miyakoshi; Yuji Kasukawa; Shin-Tai Chen; Matilda H.-C. Sheng; Jon E. Wergedal; K.-H. William Lau; David J. Baylink
This study sought to develop an in vivo gene therapy to accelerate the repair of bone fractures. In vivo administration of an engineered viral vector to promote fracture healing represents a potential high-efficacy, low-risk procedure. We selected a murine leukemia virus (MLV)-based retroviral vector, because this vector would be expected to target transgene expression to the proliferating periosteal cells arising shortly after bone fracture. This vector transduced a hybrid gene that consisted of a bone morphogenetic protein (BMP)-4 transgene with the BMP-2 secretory signal to enhance the secretion of mature BMP-4. The MLV vector expressing this BMP-2/4 hybrid gene or beta-galactosidase control gene was administered at the lateral side of the fracture periosteum at 1 day after fracture in the rat femoral fracture model. X-ray examination by radiograph and peripheral quantitative computed tomography at 7, 14, and 28 days after fracture revealed a highly significant enhancement of fracture tissue size in the MLV-BMP-2/4-treated fractures compared to the control fractures. The tissue was extensively ossified at 14 and 28 days, and the newly formed bone exhibited normal bone histology. This tissue also exhibited strong immunohistochemical staining of BMP-4. Additional control and MLV-BMP-2/4-treated animals each were monitored for 70 days to determine the fate of the markedly enhanced fracture callus. Radiographs showed that the hard callus had been remodeled and substantial healing at the fracture site had occurred, suggesting that the union of the bone at the fracture site was at least as high in the BMP-4-treated bone as in the control bone. There was no evidence of viral vector infection of extraskeletal tissues, suggesting that this in vivo gene therapy for fracture repair is safe. In summary, we have demonstrated for the first time that a MLV-based retroviral vector is a safe and effective means of introducing a transgene to a fracture site and that this procedure caused an enormous augmentation of fracture bone formation.
秋田医学 | 2009
Hiroshi Sasaki; Naohisa Miyakoshi; Yuji Kasukawa; Shigeto Maekawa; Hideaki Noguchi; Keiji Kamo; Yoichi Shimada
秋田医学 | 2008
Shigeto Maekawa; Naohisa Miyakoshi; Yuji Kasukawa; Koji Nozaka; Hideaki Noguchi; Yoichi Shimada
秋田医学 | 2008
Hideaki Noguchi; Naohisa Miyakoshi; Yuji Kasukawa; Hiroshi Sasaki; Keiji Kamo; Yoichi Shimada
Archive | 2008
Akiko Misawa; Yoichi Shimada; Naohisa Miyakoshi; Michio Hongo; Yuji Kasukawa; Shigeru Ando
/data/revues/11698330/00740005/07000890/ | 2007
Naohisa Miyakoshi; Yoichi Shimada; Yuji Kasukawa; Hidetomo Saito; Hiroyuki Kodama; Eiji Itoi
秋田医学 | 2006
Yoichi Shimada; Naohisa Miyakoshi; Michio Hongo; Yuji Kasukawa; Shigeru Ando; Eiji Itoi
秋田医学 | 2006
Koji Nozaka; Naohisa Miyakoshi; Yuji Kasukawa; Shigeto Maekawa; Hideaki Noguchi; Eiji Itoi
Akita journal of medicine | 2006
Yoichi Shimada; Naohisa Miyakoshi; Michio Hongo; Shigeru Ando; Yuji Kasukawa
Akita journal of medicine | 2006
Yoichi Shimada; Michio Hongo; Naohisa Miyakoshi; Yuji Kasukawa; Shigeru Ando; Akiko Misawa; Kunio Ebata